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Background: The prevalence of Type 2 diabetes mellitus continues to rise. Although 
glucagon-like peptide-1 (GLP-1) analog and dipeptidyl peptidase-4 (DPP-4) inhibitor 
medications are effective, there are differences between these products, including method 
of administration (injectable versus oral). The objective of this study was to examine patient 
preferences (and predictors of preferences) for two different medication profiles, one similar to 
a GLP-1 analog (liraglutide) and another similar to a DPP-4 inhibitor (sitagliptin).
Methods: Internet survey data were collected in two waves (wave 1, n = 2402; wave 2, n = 1340) 
using patients from the US and Europe. Patients were presented with two hypothetical medica-
tion profiles (“drug A” and “drug B”, resembling sitagliptin and liraglutide, respectively) and 
asked to report their preferences.
Results: Most patients in wave 1 and wave 2 reported that overall they would prefer a drug with 
the sitagliptin-like profile (81.9% and 84.4%, respectively) over a drug with the liraglutide-like 
profile (18.1% and 15.6%, respectively), and .80% of patients reported that they would be 
able to take a drug with the sitagliptin-like profile as directed by their physician for a longer 
period. The likelihood of preferring the sitagliptin-like profile significantly increased as age 
(odds ratio [OR] = 1.02) and importance placed on method of administration (OR = 1.32) 
increased (P , 0.05). Although the sitagliptin-like profile was preferred by the majority of 
patients in all subgroups, a lower proportion of patients with obesity, with weight gain, with 
A1C values above target, and who exercised preferred the sitagliptin-like profile compared 
with those without obesity (77.0% versus 87.9%), without weight gain (77.8% versus 86.7%),   
with A1C values at or below target (79.0% versus 86.5%), and who did not exercise (81.6% 
versus 86.4%), respectively (P , 0.05).
Conclusions: This research suggests that patients (across geographies) prefer an oral medica-
tion with a profile resembling sitagliptin to an injectable medication with a profile resembling 
liraglutide.
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Introduction
Type 2 diabetes mellitus (T2DM) is considered to be a major epidemic worldwide.1 
According to the International Diabetes Federation, the prevalence of diabetes is 
currently estimated at 8.5% in Europe and 11.7% in North America and the Caribbean, 
with prevalence expected to rise to 10.0% and 13.6%, respectively, by 2030.1 
As prevalence figures rise, so do health care costs. The American Diabetes Association 
previously estimated that diabetes was responsible for $116 billion in direct medical 
costs and $58 billion in indirect costs in the US in 2007.2Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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As a result of the United Kingdom Prospective Diabetes 
Study (UKPDS) and other studies, guideline committees have 
recommended that patients with TD2M maintain a hemoglobin 
A1C level of less than 7%.3,4 For many patients with T2DM, 
oral antihyperglycemic agents are used as first-line therapies 
because of the combination of efficacy and physicians’ percep-
tions of patient preference.5,6 Some oral antihyperglycemic 
agents have been associated with adverse events, such as weight 
gain and hypoglycemia, which have been linked to nonadher-
ence, treatment dissatisfaction, and diminished health-related 
quality of life (HRQoL).7–9 Partly as a consequence, persistence 
with first-line oral antihyperglycemic agents has been poor, 
with estimates in the T2DM managed care population ranging 
from 34% to 60% for discontinuation after 12 months.10,11
Dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-
like peptide-1 (GLP-1) mimetics or analogs, which rely on the 
gastrointestinal hormones that are part of the incretin system 
for the treatment of T2DM, provide a therapeutic alternative 
to common oral antihyperglycemic agents (eg, sulfonylureas, 
thiazolidinediones). These newer medications may be 
  particularly useful in cases where other therapies are not 
well tolerated or as complementary therapies when ongoing 
therapies do not allow the patient to reach their glycemic 
target.12 GLP-1 receptor agonists and DPP-4 inhibitors have 
been shown to be noninferior to other oral antihyperglyce-
mic agents, lowering mean A1C levels by 0.97% and 0.74%, 
respectively.13 Additionally, hypoglycemic episodes and 
weight gain, reported with other oral antihyperglycemic 
agents, are infrequent or absent with these new agents.14
Despite both targeting the incretin system, GLP-1 recep-
tor agonists and DPP-4 inhibitors do have several differences. 
First, all GLP-1 receptor agonists are injectable medications. 
Previous studies have shown that patients prefer additional 
oral agents over injectable agents because of fear of injec-
tions and the desire to avoid them.6,15,16 Moreover, one study 
found that persistence with these agents was poor, with only 
28.7% treatment continuation at one year follow-up among 
treatment-naïve patients with T2DM.17 Second, some GLP-1 
receptor agonists may have efficacy and weight advantages 
over DPP-4 inhibitors, suggesting a possible relationship with 
improved HRQoL because previous studies have shown an 
association between weight loss and HRQoL.16,18,19 Third, 
patients on GLP-1 therapies have reported higher rates of 
gastrointestinal-related complications, including nausea and 
vomiting, compared with DPP-4 inhibitors.18,20
Although incretin-based medications may potentially help 
to overcome some of these barriers to successful T2DM man-
agement, the positive and negative effects of these drugs should 
be further analyzed in the context of patient preference to assess 
the likelihood of long-term patient acceptability. Although phy-
sicians play a crucial role in determining the best therapeutic 
intervention for their patients, patient preferences should also 
be considered. The achievement of glycemic control goals rely 
to a large extent on treatment compliance and adherence. The 
objective of the current study was to examine patient prefer-
ences when presented with profiles similar to a GLP-1 analog 
(liraglutide) and a DPP-4 inhibitor (sitagliptin).
Patients and methods
recruitment
Data were collected in two waves with patients from the US, 
France, Italy, Germany, Spain, and the UK. Patients were 
recruited from the 2008 and 2009 US National Health and 
Wellness Survey (NHWS), an annual Internet-based ques-
tionnaire developed by Consumer Health Sciences/Kantar 
Health, and the Ailment Panel of Lightspeed Research. 
These panels are designed to be nationally representative 
and mimic the demographic composition of each country’s 
total adult population. Further details of the methodology and 
comparisons between NHWS and other sources have been 
described elsewhere.21 Participants who were over the age of 
18 years, diagnosed with T2DM by a health care professional, 
used only metformin monotherapy to treat their diabetes, 
and provided informed consent were eligible to participate 
in the study. The study protocol was approved by the Essex 
Institutional Review Board.
Wave 1 was conducted between June 2009 and July 2009, 
and wave 2 was conducted between December 2009 and 
  January 2010. All patients who completed the first wave 
(n = 2402) were recontacted and asked to participate in the 
second wave (n = 1340, 56.8% response rate). The second wave 
was conducted because newer data became available after wave 
1 from a head-to-head trial of sitagliptin and liraglutide (Novo 
Nordisk Interim Financial Report, August 6, 2009). The A1C 
efficacy difference reported in the head-to-head trial (0.6%) 
was twice that assumed in wave 1, which had been based 
on data from two different clinical trials of sitagliptin and 
liraglutide.22,23 Data from the head-to-head trial on glycemic 
efficacy and weight loss were used for the medication profiles 
in wave 2. However, because neither gastrointestinal side 
effect nor blood pressure data from the head-to-head trial were 
provided in the Novo Nordisk report, data from Nauck et al 
were used for gastrointestinal tolerability and blood pressure 
effects.22,23 The Novo Nordisk report noted that the safety data 
of liraglutide in the head-to-head study were comparable with 
what was observed in previous clinical studies of liraglutide. Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
399
Patient preference for diabetes medications
Therefore, it was deemed acceptable to use data from both trials 
in constructing the profiles. Only side effects or other effects 
that were statistically significant or clinically meaningful in 
the trials were included in the profiles.
Although the head-to-head trial suggested that sitagliptin 
was associated with a small weight loss of 1 kg, it was decided 
conservatively to assume no weight loss for sitagliptin in the 
profile. Finally, A1C baseline values were converted to average 
blood glucose values based on a published equation.24 It was 
assumed that patients would better comprehend blood glucose 
values, which are based upon day-to-day self monitoring, as 
opposed to A1C values, which are periodically tested labora-
tory measures.
Measures
Medication preference variables
Patients were shown two medication profiles at each wave of 
the study (Table 1), one of which was similar to the profile 
of sitagliptin (noted only as “drug A” to the patients) and 
the other of which was similar to liraglutide (only noted as 
“drug B”). Patients were given the following instructions: 
“Below are hypothetical descriptions of two medications 
that treat Type 2 diabetes–drug A and drug B (Note: neither 
one is an insulin). Assume taking metformin alone does not 
lower your blood sugar enough and that your physician offers 
you a choice of either drug A or drug B to be added to your 
current diabetes therapy of metformin. Assume that both 
medications cost you the same amount.” All patients were 
asked which they would prefer (drug A or drug B), which they 
would prefer to take first knowing they could later switch or 
add on other therapies if needed, and which they would be 
able to take as directed by their physician for a longer period 
of time. Additionally, for all patients who preferred drug B 
or preferred to take drug B first, they were asked whether 
their preference would change if drug A had been used by 
physicians and patients for two years and drug B had just 
become available. The patients were also asked whether their 
preference would change if drug A cost less than drug B. 
Table 1 Medication profiles shown to patients in wave 1 and wave 2
Drug A Drug B
Wave 1
how you take the medication Oral tablet taken once a day injection (needle) self-administered once a day
Blood sugar lowering efficacy if you have a blood sugar reading of 183, taking  
this oral medication can lower it to about 164  
(individual results may vary)
if you have a blood sugar reading of 183, using this injection 
medication can lower it to about 154 (individual results 
may vary)
side effects generally similar to a sugar pill with very low  
risk of hypoglycemia (ie, low blood sugar)
–   nausea (occurs in 11 to 19% of patients), vomiting (occurs 
in 5 to 7% of patients) and diarrhea (occurs in 8 to 15% 
of patients), which goes away for most patients after 
about1 month (individual results may vary)
–   Other side effects generally similar to a sugar pill with very 
low risk of hypoglycemia (ie, low blood sugar)
Other effects – Weight: no change –   Weight: loss of about 6.2 pounds (individual results may vary)
– Blood pressure: no change –   Blood pressure: decrease in systolic blood pressure of about 
2 to 3 mm of mercury (hg) (individual results may vary)
Wave 2
how you take the medication Oral tablet taken once a day injection (needle) self-administered once a day
Blood sugar lowering efficacy if you have a blood sugar reading of 197,  
taking this oral medication can lower it to  
about 171 (individual results may vary)
if you have a blood sugar reading of 197, using this 
injection medication can lower it to about 154 (individual 
results may vary)
side effects generally similar to a sugar pill with very low  
risk of hypoglycemia (ie, low blood sugar)
–   nausea (occurs in 11 to 19% of patients), vomiting (occurs 
in 5 to 7% of patients) and diarrhea (occurs in 8 to 15% of 
patients), which goes away for most patients after about 
1 month (individual results may vary)
–   Other side effects generally similar to a sugar pill with very 
low risk of hypoglycemia (ie, low blood sugar)
Other effects – Weight: no change –   Weight: loss of about 7.7 pounds (individual results 
may vary)
– Blood pressure: no change –   Blood pressure: decrease in systolic blood pressure 
of about 2 to 3 mm of mercury (hg) (individual results 
may vary)
Note: In the EU countries, blood sugar efficacy was displayed as 10.1 and 9.1 for drug A and 10.1 and 8.5 for drug B in wave 1, and 10.9 and 9.5 for drug A and 10.9 and 8.5 
for drug B in wave 2. similarly, weight loss was displayed in kilograms for drug B (2.8 kg in wave 1 and 3.5 in wave 2).Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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These additional questions were asked because, at the time 
of the surveys, sitagliptin had been available on the market 
for approximately two years and liraglutide was just being 
launched, and liraglutide is more costly than sitagliptin.
reasons for preference
After participants reported their overall preference for drug 
A or B and which drug they would prefer to take first, they 
were asked to rank the importance of the following reasons 
for their preference: how you take the medication (oral or 
injection), blood sugar lowering, side effects (nausea, vomit-
ing, and diarrhea), and other effects (weight loss and blood 
pressure decrease).
Demographics
Country of residence (US, France, Italy, Germany, Spain, 
UK), age, gender, race/ethnicity (white versus nonwhite), 
education (college/university degree versus less than college/
university degree), health insurance (yes versus no), and 
employment status (full-time, part-time, self-employed, not 
employed but looking for work, not employed and not look-
ing for work, retired, on disability, student, or homemaker) 
were assessed for all patients.
health history
Patients were asked to report the presence of comorbid dys-
lipidemia, hypertension, and obesity. Patients also reported 
any health problems experienced in the last 12 months 
(cardiovascular event, nausea or vomiting, constipation or 
diarrhea, weight gain, have not experienced any of the listed 
problems), diabetes management steps (try to maintain a 
healthy diet, try to maintain an exercise regimen, use glu-
cose monitor), diabetes educational program participation 
(yes versus no), date of last A1C test (within the last three 
months, 4–6 months ago, 7–12 months ago, over a year 
ago, or never), and what their physician said about their A1C 
level when last tested (below the target, at the target, higher 
than the target, physician did not provide test results, or do 
not remember).
statistical analysis
Preferences under each scenario (overall preference, pref-
erence if you knew you could switch later, preference for 
medication you could take longer, preference if drug B had 
just become available, and preference if drug B was more 
expensive) were reported for both study waves. All other anal-
yses focused exclusively on the overall preference assessed 
in study wave 2. Differences between the drug A and B 
preference groups were analyzed according to demographic 
and health history variables using Chi-square tests for 
categoric variables and t-tests for continuous   variables. 
Overall preference based on wave 2 data was then assessed 
in a logistic regression controlling for all demographic 
and patient characteristic variables, which were associated 
with preference with a P , 0.20 in the unadjusted analysis. 
Attribute importance items were forced into the model, 
regardless of the unadjusted P value, because these were 
directly related to preference. All analyses were performed 
using the SAS software version 9.1.
Results
In wave 1, 2402 patients completed the survey, comprising 
400 patients from each country (with the exception of 
402 patients from France). Patients were equally split between 
male (n = 1222, 50.9%) and female (n = 1180, 49.1%), 
although patients were mostly white (n = 2057, 85.6%), had 
health insurance (n = 1611, 67.1%), and had less than a college/
university degree (n = 1717, 71.5%). The mean age across the 
sample was 54.5 (standard deviation [SD] = 12.7) years.
Based on the medication profiles provided, the majority 
of patients (81.9%) responded that overall they would prefer 
the drug with the sitagliptin-like profile (drug A) over the 
drug with the liraglutide-like profile (drug B), prefer to take 
the drug with the sitagliptin-like profile first (82.8%), and 
believed they could take the drug with the sitagliptin-like 
profile for longer (83.4%, Table 2). Among the patients 
who preferred the liraglutide-like profile (drug B) overall or 
preferred to take a drug with the liraglutide-like profile first 
(n = 292), 63.7% maintained their preference if told the drug 
Table 2 Frequency and percentage of patients who chose each 
medication under varying scenarios
Drug A 
(sitagliptin- 
like profile)
Drug B 
(liraglutide-
like profile)
n % n %
Wave 1 preferences
Which drug would you prefer 1098 81.9% 242 18.1%
Which drug would you prefer to  
take first if you could switch later
1110 82.8% 230 17.2%
Which drug could you take for  
longer
1117 83.4% 223 16.6%
Wave 2 preferences
Which drug would you prefer 1131 84.4% 209 15.6%
Which drug would you prefer to  
take first if you could switch later
1139 85.0% 201 15.0%
Which drug could you take for longer 1159 86.5% 181 13.5%
Note: Significantly more patients preferred drug A in each scenario (p’s , 0.001).Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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with the liraglutide-like profile had just become available, 
and 65.1% maintained their preference if a drug with the 
liraglutide-like profile was more expensive.
In wave 2, out of the total sample (n = 1340), 266 
(19.9%) participants were from Germany, 111 (8.3%) were 
from France, 212 (15.8%) were from Italy, 208 (15.5%) 
were from Spain, 265 (19.8%) were from the UK, and 278 
(20.8%) were from the US. The majority of participants were 
male (n = 713, 53.2%), white (n = 1213, 90.5%), had health 
insurance (n = 881, 65.7%), and had less than a college/
university degree (n = 943, 70.4%). The mean age across 
the wave 2 sample was 55.4 (SD = 12.1) years. Those who 
participated in both wave 1 and wave 2 were significantly 
older (55.4 years versus 53.4 years, respectively, P , 0.001), 
and more likely to be white (90.5% versus 79.5%, P , 0.001) 
and male (53.2 versus 47.9, P = 0.01) than those who only 
participated in wave 1.
Although the glycemic efficacy of the drug with the 
liraglutide-like profile was improved in the medication profile 
in wave 2, the preference results were consistent with wave 1. 
Most patients (84.4%) responded they would prefer the drug 
with the sitagliptin-like profile (drug A) over the drug with 
the liraglutide-like profile (drug B) overall, prefer to take 
the drug with the sitagliptin-like profile first (85.0%), and 
believed they could take the drug with the sitagliptin-like 
profile longer (86.5%, Table 2). Among those patients who 
preferred the liraglutide-like profile overall or preferred to 
take the drug with the liraglutide-like profile first (n = 251), 
57.0% maintained their preference if told the drug had just 
become available, and 71.3% maintained their preference if 
told the drug was more expensive.
The reasons for the overall preference in wave 2 were 
then compared between patients who preferred the drug with 
the sitagliptin-like profile and those who preferred the drug 
with the liraglutide-like profile (Table 3). “How you take the 
medication, oral versus injectable” was ranked as the most 
important reason for their preference by the majority of 
those who preferred the drug with the sitagliptin-like profile 
(57.5%). Conversely, “blood sugar lowering” was ranked as 
the most important reason for their preference by the major-
ity of those who preferred the drug with the liraglutide-like 
profile (56.0%). All reasons were ranked differently between 
the preference groups. Specifically, for patients who pre-
ferred the drug with the sitagliptin-like profile, “how you 
take the medication” (57.5% versus 12.9%, P , 0.001) 
and “side effects” (17.9% versus 4.3%, P , 0.001) were 
significantly more likely to be ranked as the most important 
reason for their preference. Conversely, for patients who 
preferred the drug with the liraglutide-like profile, “blood 
sugar lowering” (56.0% versus 23.1%, P , 0.001) and “other 
effects” (26.8% versus 1.6%, P , 0.001) were significantly 
more likely to be ranked as the most important reason for 
their preference.
Group differences were then analyzed between patients 
with a preference for the drug with the sitagliptin-like 
profile and patients with a preference for the drug with 
the liraglutide-like profile (Table 4). Patients who preferred 
the sitagliptin-like profile were significantly older, and were 
less likely to be female, be white, have comorbid obesity, 
have experienced weight gain in the past 12 months, have 
maintained a healthy diet, have maintained an exercise regi-
men, have participated in a diabetes educational program, 
and have higher A1C levels than their targets the last time they 
were tested (all P , 0.05). Differences among countries and 
employment groups were also observed (all P , 0.05).
Logistic regression was conducted and included all 
predictors of overall preference in wave 2 at the P , 0.20 
level, as well as all attribute importance items (Table 5). The 
likelihood of preferring the sitagliptin-like profile signifi-
cantly increased with increasing age (odds ratio [OR] = 1.02, 
95% confidence interval [CI]: 1.01–1.04) or the importance 
placed on method of administration (oral versus injectable, 
OR = 1.32, 95% CI: 1.15–1.52). Conversely, the likelihood of 
preferring the sitagliptin-like profile was significantly lower 
in those with obesity (OR = 0.54, 95% CI: 0.38–0.75), weight 
gain in the last year (OR = 0.62, 95% CI: 0.44–0.87), those 
with an A1C above target (OR = 0.59, 95% CI: 0.41–0.83), and 
those who tried to maintain an exercise regimen (OR = 0.68, 
95% CI: 0.49–0.96), compared with those without obesity, 
without weight gain in the last year, those with A1C at or 
below target, and those who did not try to maintain an exer-
cise regimen, respectively. Although the odds for preferring 
Table 3 reasons for preference ranked by importance
Ranked 1st
Drug A 
(sitagliptin-like 
profile)
Drug B 
(liraglutide-
like profile)
n % n %
how you take the medication 
(oral or injection)
650 57.5%a 27 12.9%
Blood sugar lowering 261 23.1% 117 56.0%a
side effects (nausea, vomiting, 
and diarrhea)
202 17.9%a 9 4.3%
Other effects (weight loss 
and blood pressure decrease)
18 1.6% 56 26.8%a
Note: aThe percentage of patients who noted each reason as the most important 
was significantly different between the two groups (p , 0.001).Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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Table 4 Patient characteristics and overall medication preference
Total Drug A (sitagliptin- 
like profile)  
n = 1131 (84.4%)
Drug B (liraglutide- 
like profile)  
n = 209 (15.6%)
P
n % of total  
sample
n Row % n Row %
Country ,0.001
germany 266 19.9% 214 80.5% 52 19.5%
France 111   8.3% 99 89.2% 12 10.8%
italy 212 15.8% 185 87.3% 27 12.7%
spain 208 15.5% 188 90.4% 20 9.6%
United Kingdom 265 19.8% 205 77.4% 60 22.6%
United states 278 20.8% 240 86.3% 38 13.7%
Gender 0.01
Male 713 53.2% 619 86.8% 94 13.2%
Female 627 46.8% 512 81.7% 115 18.3%
Employment 0.01
employed full-time 425 31.7% 357 84.0% 68 16.0%
employed part-time 120   9.0% 96 80.0% 24 20.0%
self-employed 99   7.4% 88 88.9% 11 11.1%
not employed, but  
looking for work
51   3.8% 42 82.4% 9 17.6%
not employed and  
not looking for work
18   1.3% 10 55.6% 8 44.4%
retired 433 32.3% 381 88.0% 52 12.0%
On disability 107   8.0% 80 74.8% 27 25.2%
student 8   0.6% 6 75.0% 2 25.0%
homemaker 79   5.9% 71 89.9% 8 10.1%
Insurance status 0.06
no health insurance 459 34.3% 375 81.7% 84 18.3%
health insurance 881 65.8% 756 85.8% 125 14.2%
Race 0.04
non-white 127   9.5% 114 89.8% 13 10.2%
White 1213 90.5% 1017 83.8% 196 16.2%
Education 0.84
Less than college/ 
university degree
944 70.5% 798 84.5% 146 15.5%
college/university degree 396 29.6% 333 84.1% 63 15.9%
Diagnosed comorbidity
Dyslipidemia 571 42.6% 478 83.7% 93 16.3% 0.55
hypertension 641 47.8% 531 82.8% 110 17.2% 0.13
Obesity 430 32.1% 331 77.0% 99 23.0% ,0.001
Health problems  
in last 12 months
cardiovascular event  
(eg, heart attack, stroke)
39   2.9% 29 74.4% 10 25.6% 0.15
nausea or vomiting 217 16.2% 174 80.2% 43 19.8% 0.09
constipation or diarrhea 515 38.4% 432 83.9% 83 16.1% 0.68
Weight gain 343 25.6% 267 77.8% 76 22.2% ,0.001
Diabetes management steps
i try to maintain a healthy diet 1054 78.7% 877 83.2% 177 16.8% 0.01
i try to maintain an  
exercise regimen
559 41.7% 456 81.6% 103 18.4% 0.02
i use a glucose monitor  
and test strips
835 62.3% 693 83.0% 142 17.0% 0.06
Participated in diabetes  
educational program
0.03
Yes 471 35.2% 383 81.3% 88 18.7%
no 869 64.9% 748 86.1% 121 13.9%
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Table 4 (Continued)
Total Drug A (sitagliptin- 
like profile)  
n = 1131 (84.4%)
Drug B (liraglutide- 
like profile)  
n = 209 (15.6%)
P
n % of total  
sample
n Row % n Row %
Time of last A1C test 0.42
Within the past 3 months 823 61.4% 691 84.0% 132 16.0%
4–6 months ago 310 23.1% 265 85.5% 45 14.5%
7–12 months ago 113 8.4% 91 80.5% 22 19.5%
Over a year ago 59 4.4% 53 89.8% 6 10.2%
never 35 2.6% 31 88.6% 4 11.4%
What doctor said at last test  
(of those who had a test)
0.02
A1c was below the target 220 16.4% 188 85.5% 32 14.6%
A1c was at the target 533 39.8% 466 87.4% 67 12.6%
A1c was higher than the target 371 27.7% 293 79.0% 78 21.0%
My physician did not provide  
me with the lab results
83 6.2% 67 80.7% 16 19.3%
i don’t remember 98 7.3% 86 87.8% 12 12.2%
M SD M SD M SD P
Age 55.35 12.13 55.89 12.13 52.45 11.79 ,0.001
Years of T2DM diagnosed 6.24 5.88 6.22 5.87 6.35 5.95 0.78
Importance of diabetes  
medication attributes 
(unimportant to important)
side effects 3.92 1.17 3.91 1.19 3.98 1.04 0.35
Method of administration  
(oral vs injectable)
3.86 1.23 3.90 1.22 3.65 1.29 0.008
effectiveness of medication 4.49 0.84 4.47 0.85 4.55 0.77 0.26
experience of prescribing  
physician with medication
4.11 0.96 4.10 0.97 4.13 0.85 0.67
Out-of-pocket costs  
of medication
3.42 1.43 3.42 1.43 3.43 1.46 0.94
the sitagliptin-like profile were significantly lower, there 
was an overall preference for the sitagliptin-like profile in 
these subgroups (adjusted percentages for preferring the 
sitagliptin-like profile: those with obesity = 77.0% versus 
those without obesity = 87.9%; those who experienced 
weight gain in the last year = 77.8% versus those who did 
not experience weight gain in the last year = 86.7%; those 
with an A1C above target = 79.0% versus those with an A1C at/
below target = 86.5%; those who tried to maintain an exercise 
regimen = 81.6% versus those who did not try to maintain 
an exercise program = 86.4%). No other variable, including 
country, was a significant predictor of preference.
Discussion
Medication preferences for hypothetical sitagliptin-like and 
liraglutide-like agents were assessed in T2DM patients taking 
metformin monotherapy who would be eligible to add a new 
diabetes drug if they could not adequately control their blood 
sugar with metformin. Significantly more patients preferred 
the sitagliptin-like profile. Patients also were significantly 
more likely to prefer to take the drug with the sitagliptin-
like profile first and more likely to report that they could 
take the drug with the sitagliptin-like profile as directed by 
their physician for a longer period of time. Among those 
who preferred the liraglutide-like profile, approximately 
one-third would have preferred the sitagliptin-like profile 
if the liraglutide-like drug was newer or more expensive. 
It is important to note that these preferences were consistent 
between wave 1 and wave 2. Although wave 2 used a 
liraglutide-like profile with greater weight reduction and 
glycemic efficacy relative to wave 1, this essentially had no 
effect on preferences.
Because of the liraglutide-like profile’s weight loss and 
glycemic efficacy attributes, it was not surprising that a 
smaller proportion of patients with obesity, with weight gain 
in the last year, with A1C values above target, or who tried to 
maintain an exercise regimen preferred the sitagliptin-like 
profile compared with those without obesity, without weight Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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gain in the last year, with A1C values at or below target, or 
who did not try to maintain an exercise regimen. Although 
these factors significantly increased the number of patients 
who preferred the liraglutide-like profile, the vast majority 
of patients still preferred the sitagliptin-like profile in these 
subgroups. Conversely, a higher proportion of patients who 
were older and who placed more importance on the method 
of administration preferred the sitagliptin-like profile 
compared with those who were younger and who placed less 
importance on the method of administration. These findings 
coincide with the stated reasons for preference, because the 
majority of those who preferred the sitagliptin-like profile 
ranked method of administration as the most important 
factor. Similarly, the majority of those who preferred the 
liraglutide-like profile ranked glycemic efficacy and weight 
loss as the most important factors. Overall, these findings 
suggest an overwhelming preference among T2DM patients 
for an oral medication with a profile like the DPP-4 inhibitor, 
sitagliptin, even with slightly lower glycemic efficacy and 
a neutral weight loss profile. When patients were given the 
opportunity to change their preference if the drug with the 
liraglutide-like profile was newer or more expensive, about 
one-third of patients did so. The results of our survey are 
generally consistent with the findings of a recent study by 
Jendle et al, which demonstrated that Swedish patients with 
T2DM were willing to pay considerable amounts of money to 
avoid injections and nausea, and to lose weight and achieve 
better efficacy.25
These results should also be considered within the con-
text of recent health technology assessment agency activity. 
The National Institute for Health and Clinical Excellence 
(NICE) approved the use of liraglutide but, at the time of 
writing, only for a 1.2 mg dosage and only when taken in 
conjunction with two other medications.26 The 1.2 mg dosage 
would provide efficacy similar to that of the wave 1 profile 
and a lower efficacy than tested in the wave 2 profile. Yet, 
because preferences did not shift between the two waves, this 
recommended lower dosage would not likely have had any 
meaningful effect on our results. However, the liraglutide-
like profile did not mention that two additional medications 
would be needed if it was selected, as would be the case given 
NICE’s decision. It is conceivable that this could further 
reduce the preference for the liraglutide-like profile, although 
it is unclear to what extent.
Finally, it should be noted that full results of the head-
to-head trial of sitagliptin and liraglutide were reported after 
completion of our study.18 The blood glucose reduction and 
weight loss results were almost exactly what was found in the 
wave 2 survey. The incidence of nausea was 21% and 27% 
for liraglutide 1.2 mg and 1.8 mg, respectively, versus 5% for 
sitagliptin, and the incidence of vomiting was 8% and 10% 
for liraglutide 1.2 mg and 1.8 mg, respectively, versus 4% for 
sitagliptin. These values were slightly higher than those used 
in our survey (based on Nauck et al).22,23 The incidence of 
diarrhea was 7% and 11% for liraglutide 1.2 mg and 1.8 mg, 
respectively, versus 5% for sitagliptin, and these values were 
slightly lower for liraglutide and slightly higher for sitagliptin 
than those used in our survey. Overall, however, the differ-
ences between the final study results and our assumptions 
based on the Novo Nordisk Interim Financial Report and the 
Nauck et al studies were small.22,23 In the head-to-head trial 
Table 5 Likelihood of preference for the drug with the sitagliptin-
like profile (drug A) over the drug with the liraglutide-like profile 
(drug B)
OR (95% CI) P
germany 0.82 (0.48–1.41) 0.47
France 1.79 (0.80–3.99) 0.16
italy 1.92 (0.97–3.79) 0.06
spain 1.92 (0.98–3.73) 0.06
UK 0.86 (0.45–1.64) 0.64
Us (reference) – –
Age 1.02 (1.01–1.04) 0.003
Male 1.30 (0.93–1.80) 0.12
White 0.57 (0.29–1.14) 0.11
employeda 1.08 (0.76–1.53) 0.67
have health insurance 1.26 (0.75–2.12) 0.39
Diagnosed hypertension 0.99 (0.71–1.39) 0.96
Obesity 0.54 (0.38–0.75) ,0.001
cardiovascular event in last year 0.50 (0.22–1.12) 0.09
nausea or vomiting in last year 0.93 (0.62–1.41) 0.74
Weight gain in last year 0.62 (0.44–0.87) 0.01
Maintain a healthy diet 0.81 (0.51–1.28) 0.37
Maintain an exercise regimen 0.68 (0.49–0.96) 0.03
Use of glucose monitor  
and test strips
0.78 (0.55–1.10) 0.16
Participated in diabetes  
educational program
0.83 (0.59–1.16) 0.27
A1c at or below target (reference) – –
A1c above target 0.59 (0.41–0.83) 0.006
A1c unknown/not remembered 0.80 (0.48–1.31) 0.36
importance of side effects 1.01 (0.86–1.18) 0.91
importance of method  
of administration
1.32 (1.15–1.52) ,0.001
importance of effectiveness  
of medication
0.79 (0.62–1.01) 0.05
importance of experience of  
prescribing physician with medication
0.93 (0.77–1.13) 0.49
importance of out-of-pocket  
costs of medication
1.00 (0.88–1.13) 0.98
Note:  aDue to small sample sizes in some of the employment categories, those 
who were currently employed (full-time, part-time, or self-employed) were grouped 
together and compared with all other categories (which collectively served as the 
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there was no difference in treatment satisfaction using the 
Diabetes Treatment Satisfaction Questionnaire between the 
liraglutide 1.2 mg dose and sitagliptin, but there was a sta-
tistically significant difference in favor of liraglutide 1.8 mg 
compared with sitagliptin (+1.39; P , 0.05). Important to 
consider, however, is that patients who agreed to participate 
in this open-label, head-to-head trial would have been will-
ing to be randomized to an injectable medication; those 
patients who refused to accept injectable medication would 
not have been enrolled in this trial. The results of our study 
suggest that, in real clinical practice, a majority of patients on 
metformin monotherapy are not willing to take an injectable 
medication with an overall profile like liraglutide when an 
alternative like sitagliptin exists. Further research is clearly 
warranted.
Several limitations of this research should be considered. 
The sitagliptin and liraglutide profiles were simplified for 
purposes of a large, multinational, Internet-based survey. 
Although the clinical trials from which these profiles were 
derived noted no other statistically significant and/or clini-
cally relevant side or other effects, it is conceivable that small, 
rare, or unknown effects of these drugs could impact treat-
ment preference. Sitagliptin has been on the market for a few 
years and has more clinical trial evidence than liraglutide, 
which has just recently been launched. A pooled safety study 
of sitagliptin was published in 2010 after completion of our 
study.27 That study combined results from 19 double-blind 
clinical studies (n = 5429 exposed to sitagliptin and 4817 
not exposed) with up to two years of follow-up. The pooled 
results suggest the risk of specific adverse events is similar 
in the sitagliptin-exposed and sitagliptin-nonexposed groups, 
except for hypoglycemia and diarrhea risk being greater in 
the nonexposed group (associated with sulfonylurea and met-
formin use, respectively) and constipation risk being greater 
in the sitagliptin-exposed group. All other adverse events 
were rare and/or of borderline or no statistical significance. 
Therefore, we feel the profile for sitagliptin is reasonably 
accurate in our study.
Patients with certain conditions (eg, thyroid cancer, 
chronic kidney disease) may not be eligible for certain 
medications or may be restricted in their dosage (which 
could have implications on the risk-benefit profiles). These 
types of factors were not included in the profiles and may 
have influenced the preferences for a select group of patients 
with those conditions.
In real clinical practice, the physician would provide 
the patient with information on the risks and benefits of 
the various treatment options and would be available to 
answer any questions the patient may have. The current 
study   standardized the information presented. The actual 
experience of being on these medications may be difficult 
for patients to conceptualize from these survey profiles (and 
patients did not have the opportunity to clarify any ambiguity 
in the risks and benefits, as they could in a real-world envi-
ronment). For example, the risk of nausea may be mitigated 
by physician instruction about proper titration, but this vari-
ability in nausea incidence could not be easily conveyed in 
a survey environment. Because of all of these factors, actual 
preference rates may be different from those reported here.
Finally, it is unclear to what extent the current sample 
of diabetes patients represents the general diabetes patient 
population on metformin monotherapy. Although the sample 
was geographically diverse, and the sampling structure of 
the NHWS (as a whole) mimics the demographic composi-
tion of individual countries, it is possible that our diabetes 
sample may differ in meaningful ways from the overall   
population.
Conclusion
In summary, patients preferred the sitagliptin-like profile to 
that of the liraglutide-like profile. These preferences were 
largely the same across Europe and the US. Because patients 
reported that they would be able to take the drug with the 
sitagliptin-like profile as directed by their physician for a 
longer period of time, further research is needed in order to 
determine the effect these preferences would have on treat-
ment adherence and subsequent health outcomes.
Disclosure
Drs Girman, Brodovicz, Zhang, Qiu, Pentakota, and   Radican 
are employees of Merck and Co., Inc., which provided 
  funding to Kantar Health for the fielding and analysis of 
the current study. Dr DiBonaventura and Mr Wagner are 
employees of Kantar Health.
References
1.  International Diabetes Federation (2009). IDF Diabetes Atlas. Available 
from: http://www.diabetesatlas.org/content/regional-overview. Accessed 
2010 May 26.
2.  Centers for Disease Control and Prevention. National diabetes fact sheet: 
General information and national estimates on diabetes in the United 
States, 2007. Available from: http://www.cdc.gov/diabetes/pubs/pdf/
ndfs_2007.pdf. Accessed 2010 May 26.
3.  Stephens JM, Botteman MF, Hay JW. Economic impact of antidiabetic 
medications and glycemic control on managed care organizations: A review 
of the literature. J Manag Care Pharm. 2006;12(2):130–142.
4.  American Diabetes Association. Standards of Medical Care in Diabetes – 
2010. Diabetes Care. 2010;Suppl 1:S11–S61.
5.  Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: 
  Scientific review. JAMA. 2002;287(3):360–372.Patient Preference and Adherence
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/patient-preference-and-adherence-journal
Patient Preference and Adherence is an international, peer-reviewed, 
open access journal focusing on the growing importance of patient 
preference and adherence throughout the therapeutic continuum. Patient 
satisfaction, acceptability, quality of life, compliance, persistence and 
their role in developing new therapeutic modalities and compounds to 
optimize clinical outcomes for existing disease states are major areas of 
interest. This journal has been accepted for indexing on PubMed Central. 
The manuscript management system is completely online and includes a 
very quick and fair peer-review system. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
406
DiBonaventura et al
  6.  Joy SV . Clinical pearls and strategies to optimize patient outcomes. 
Diabetes Educ. 2008;34 Suppl 3:54S–59S.
  7.  Brunton S. Beyond glycemic control: Treating the entire type 2 diabetes 
disorder. Postgrad Med. 2009;121(5):68–81.
  8.  Pollack MF, Purayidathil FW, Bolge SC, Williams SA. Patient-reported 
tolerability issues with oral antidiabetic agents: Associations with adher-
ence; treatment satisfaction and health-related quality of life. Diabetes 
Res Clin Pract. 2010;87(2):204–210.
  9.  Marrett E, Stargardt T, Mavros P, Alexander CM. Patient-reported 
outcomes in a survey of patients treated with oral antihyperglycaemic 
medications: Associations with hypoglycaemia and weight gain. Dia-
betes Obes Metab. 2009;11(12):1138–1144.
  10.  Barron J, Wahl P, Fisher M, Plauschinat C. Effect of prescription 
copayments on adherence and treatment failure with oral antidiabetic 
medications. P T. 2008;33(9):532–553.
  11.  Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence 
and persistence across 6 chronic medication classes. J Manag Care 
Pharm. 2009;15(9):728–740.
  12.  Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an 
American Association of Clinical Endocrinologists/American College 
of Endocrinology consensus panel on type 2 diabetes mellitus: An 
algorithm for glycemic control. Endocr Pract. 2009;15(6):540–559.
  13.  Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy 
in type 2 diabetes: Systematic review and meta-analysis. JAMA. 2007; 
298(2):194–206.
  14.  Zarowitz BJ, Conner C. The intersection of safety and adherence: 
New incretin-based therapies in patients with type 2 diabetes mellitus. 
Pharmacotherapy. 2009;29(12 Pt 2):55S–67S.
  15.  Khan H, Coyle FM, Chowdhury TA. Patients’ preference for subsequent 
therapy following secondary failure of metformin and sulphonylurea. 
Pract Diabetes Int. 2009;26(7):282–284.
  16.  Hayes RP, Bowman L, Monahan PO, Marrero DG, McHorney CA. 
Understanding diabetes medications from the perspective of patients 
with type 2 diabetes: Prerequisite to medication concordance. Diabetes 
Educ. 2006;32(3):404–414.
  17.  Cooke CE, Lee HY, Tong YP, Haines ST. Persistence with injectable 
antidiabetic agents in members with type 2 diabetes in a commercial man-
aged care organization. Curr Med Res Opin. 2010;26(1):231–238.
  18.  Pratley RE, Nauck MA, Bailey T, et al. Liraglutide versus sitagliptin 
for patients with type 2 diabetes who did not have adequate glycaemic 
control with metformin: A 26-week, randomised, parallel-group, open-
label trial. Lancet. 2010;375(9724):1447–1456.
  19.  Fine JT, Colditz GA, Coakley EH, et al. A prospective study of weight 
change and health-related quality of life in women. JAMA. 1999; 
282(22):2136–2142.
  20.  Tiessen RG, Castaigne JP, Dreyfus JF, Nemansky M, Kruizinga HH, 
van Vliet AA. Pharmacokinetics and tolerability of a novel long-acting 
glucagon-like peptide-1 analog, CJC-1131, in healthy and diabetic 
subjects. Int J Clin Pharmacol Ther. 2008;46(9):443–452.
  21.  Bolge SC, Doan JF, Kannan H, Baran RW. Association of insomnia 
with quality of life, work productivity, and activity impairment. Qual 
Life Res. 2009;18(4):415–422.
  22.  Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy 
and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared 
with the sulfonylurea, glipizide, in patients with type 2 diabetes inad-
equately controlled on metformin alone: A randomized, double-blind, 
non-inferiority trial. Diabetes Obes Metab. 2007;9(2):194–205.
  23.  Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison 
of liraglutide, glimepiride, and placebo, all in combination with met-
formin, in type 2 diabetes. Diabetes Care. 2009;32(1):84–90.
  24.  Nathan DM, Kuenen J, Borg R, et al. Translating the A1C assay 
into estimated average glucose values. Diabetes Care. 2008;31(8): 
1473–1478.
  25.  Jendle J, Torffvit O, Ridderstråle M, et al. Willingness to pay for health 
improvements associated with anti-diabetes treatments for people with 
type 2 diabetes. Curr Med Res Opin. 2010;26(4):917–923.
  26.  National Institute for Health and Clinical Excellence. NICE appraisal 
of liraglutide for type 2 diabetes mellitus. Available from: http://www.
nice.org.uk/media/C2F/63/2010015Type2DiabetesLiraglutide.pdf. 
Accessed 2010 May 26.
  27.  Williams-Herman D, Engel SS, Round E, et al. Safety and tolerability 
of sitagliptin in clinical studies: A pooled analysis of data from 10,246 
patients with type 2 diabetes. BMC Endocr Disord. 2010;10:7.